Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57449 | 0.92 | MAPT (0.42) | MAPTALDH1A1KCNH3TAAR1MAOA | |
| SCHEMBL629259 | 0.85 | MAPT (0.38) | MAPTALDH1A1KCNH3TAAR1GRM5 | |
| SCHEMBL978043 | 0.80 | MAPT (0.42) | MAPTALDH1A1KCNH3TAAR1MAOA | |
| SCHEMBL31687255 | 0.79 | MAPT (0.52) | MAPTALDH1A1KCNH3L3MBTL1LMNA | |
| Benzene SCHEMBL28332770 | 0.78 | MAPT (0.43) | MAPTALDH1A1KCNH3TAAR1GRM5 | |
| SCHEMBL114143 | 0.78 | MAPT (0.43) | MAPTALDH1A1KCNH3TAAR1GRM5 | |
| SCHEMBL31687718 | 0.78 | MAPT (0.50) | MAPTALDH1A1KCNH3L3MBTL1LMNA | |
| SCHEMBL31687729 | 0.78 | MAPT (0.50) | MAPTALDH1A1KCNH3L3MBTL1LMNA | |
| SCHEMBL31687723 | 0.78 | MAPT (0.50) | MAPTALDH1A1KCNH3L3MBTL1LMNA | |
| SCHEMBL15360346 | 0.77 | MAPT (0.48) | MAPTALDH1A1KCNH3TAAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981138-B2 | Method for producing aminoorganosilanes | WACKER CHEMIE AG (DE) | 2015-03-17 | — | — | US | disclosed |
| US-20120071650-A1 | METHOD FOR PRODUCING AMINOORGANOSILANES | WACKER CHEMIE AG (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071650-A1 | METHOD FOR PRODUCING AMINOORGANOSILANES | NR1I3, NR1H4, MSRB3 | MAPT 3742/4885ALDH1A1 2497/4885KCNH3 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.